777865-57-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-bromophenyl)methyl-2-methyl-1H-imidazole is used as a chemical intermediate for the development of antifungal and antiparasitic drugs due to its unique molecular structure and potential medicinal properties.
Used in Organic Synthesis:
1-(4-bromophenyl)methyl-2-methyl-1H-imidazole is used as a building block in organic synthesis for creating other chemical compounds, leveraging its imidazole and bromophenyl groups to form novel molecules with various applications.
Used in Research and Development:
1-(4-bromophenyl)methyl-2-methyl-1H-imidazole is used as a research compound to study its properties, potential applications, and to understand its effects when combined with other substances. This can lead to the discovery of new drugs or materials with beneficial properties.

Upstream product

• 693-98-1 2-methylimidazole 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 106-38-7 para-bromotoluene 

Downstream Products

• 1349778-52-4 Br^(1-)*C₂₇H₂₄BrN₂O⁽¹⁺⁾ 
• 1349778-37-5 Br^(1-)*C₂₇H₂₂BrN₂⁽¹⁺⁾ 
• 1349778-62-6 Br^(1-)*C₂₇H₂₂BrCl₂N₂O⁽¹⁺⁾ 
• 1349778-46-6 C₂₇H₁₉BrCl₂N₂ 

Relevant academic research and scientific papers

Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor

The phosphoinositide 3-kinase (PI3K) family is one of the most frequently activated enzymes in a wide range of human cancers; thus, inhibition of PI3K represents a promising strategy for cancer therapy. Herein, a series of benzylamine substituted arylsulfonamides were designed and synthesized as dual PI3K/mTOR inhibitors using a strategy integrating focused library design and virtual screening, resulting in the discovery of 13b (NSC765844). The compound 13b exhibits highly potent enzyme inhibition with IC50s of 1.3, 1.8, 1.5, 3.8 and 3.8?nM for PI3Kα, β, γ, δ, and mTOR, respectively. 13b was further evaluated in NCI by an in?vitro cytotoxic screening program. Broad-spectrum antitumor activities with mean GI50value of 18.6?nM against approximately 60 human tumor cell lines were found. 13b displayed favorable physicochemical properties and superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in?vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug candidate.

Design, synthesis, and biological evaluation, of the first selective nonpeptide AT2 receptor agonist

The first druglike selective angiotensin II AT2 receptor agonist (21) with a Ki value of 0.4 nM for the AT2 receptor and a Ki > 10 μM for the AT1 receptor is reported. Compound 21, with a bioavailability of 20-3